Ariad
Data from the meeting suggest that lung cancer patients with ALK-positive tumors may soon have two first-line options and more choices when their disease progresses.
Originally published Oct. 14.
Originally published Jan. 10.
Ariad Pharmaceuticals is planning to resume marketing its leukemia drug Iclusig (ponatinib) in mid-January, with a narrower indication for a genetically-defined population and for those with unmet medical needs.
Drugmakers in Third Quarter Focus on Uptake of Newer Personalized Rx to Replace Older Versions
Premium
Originally published Nov. 5.
Ariad Stops Iclusig Sales Due to Serious AEs; Would a CDx Have Changed Risk/Benefit Profile?
Premium
This article has been updated with a statement from the FDA and to clarify that MolecularMD withdrew its PMA for the T315I companion test after the FDA deemed it not necessary to support Iclusig's administration. Originally published Nov. 1.
Aug 14, 2013
Dec 19, 2012
Sep 18, 2012
MolecularMD Withdraws PMA for Leukemia CDx
Jun 14, 2012
Feb 27, 2009
Feb 27, 2009